Optimal Labeling For Opsumit Allows Actelion To Drop Promotion Of Tracleer

With a ‘clean’ label that differentiates macitentan from current standard of care, Actelion’s got what it wanted from FDA: a newly approved next-generation drug with a long patent life that can expand its presence in the pulmonary arterial hypertension market, and, importantly, protect its core franchise from upcoming generic competition.

Actelion Pharmaceuticals Ltd.’s newly approved drug for pulmonary arterial hypertension, Opsumit (macitentan), is differentiated enough for the company to drop promotion in the U.S. of its major product, Tracleer, and commit its resources to the new follow-on.

On a conference call with analysts Oct. 21, Chief Operating Officer Otto Schwarz said that the company’s U.S

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pricing Debate

More from Market Access